Skip to Content

'
Jonathan M. Kurie, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

The current research of the Kurie Laboratory is centered on the investigation of mechanisms of lung cancer metastasis for the purpose of identifying novel therapeutic targets. Of foremost interest is to understand how the cellular and extracellular matrix constituents of the tumor microenvironment are controlled by tumor cells, and how signals from the microenvironment influence tumor cell behavior. In this effort, the Kurie lab uses cellular models, genetic mouse models of lung cancer that recapitulate key somatic genetic mutations and epigenetic events in tumor cells, and a tissue bank of molecularly and clinically annotated human lung cancers and matched normal lung. Dr. Kurie has been mentoring postdoctoral fellows, graduate students, and technicians, and has received the Mentor of the Year Award at MD Anderson in 2012. He has been actively involved in the career development of several researchers, some of whom have gone on to establish them self as independent investigators and physician scientists.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3030
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1983 East Carolina University, Greenville, NC, MD, Medicine
1979 University of North Carolina, Chapel Hill, NC, BA, Chemistry

Postgraduate Training

7/1988-6/1993 Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY, Ethan Dmitrovsky, MD
7/1986-6/1988 Biotechnology Fellow, Laboratory of Genetics, National Institutes of Health, National Cancer Institute, Bethesda, MD, Michael Potter, MD
7/1984-6/1986 Resident, Medical College of Georgia, Augusta, GA
7/1983-6/1984 Intern, Medical College of Georgia, Augusta, GA

Board Certifications

1/2010 Medical Oncology Subspecialty
1/1986 American Board of Internal Medicine

Experience/Service

Institutional Committee Activities

Member, Research Faculty Hiring Committee, 2013-present
Member, ASCO YIA Oversight Committee, 2011-present
Member, Laboratory Space Subcommittee, 1/2004-2008

Honors and Awards

2013 The Julie and Ben Rogers Award of Excellence in Research Finalist, The University of Texas MD Anderson Cancer Center
2012 Potu N. Rao Award for Excellence in Basic Science, The University of Texas MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124(6):2696-708, http://www.jci.org, 6/2014. e-Pub 6/2014.
2. Gill BJ, Gibbons DL, Roudsari LC, Saik JE, Rizvi ZH, Roybal JD, Kurie JM, West JL. A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. Cancer Res 72(22):6013-23, 11/2012. e-Pub 9/2012. PMCID: PMC3632398.
3. Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) 4(6):818-28, 6/2011. PMCID: PMC3108499.
4. Borok Z, Whitsett JA, Bitterman PB, Thannickal VJ, Kotton DN, Reynolds SD, Krasnow MA, Bianchi DW, Morrisey EE, Hogan BL, Kurie JM, Walker DC, Radisky DC, Nishimura SL, Violette SM, Noble PW, Shapiro SD, Blaisdell CJ, Chapman HA, Kiley J, Gail D, Hoshizaki D. Cell plasticity in lung injury and repair: report from an NHLBI workshop, April 19-20, 2010. Proc Am Thorac Soc 8(3):215-22, 6/2011. PMCID: PMC3132783.
5. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, Alvarez CA, Moreira DC, Creighton CJ, Gregory PA, Goodall GJ, Kurie JM. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 121(4):1373-1385, 4/2011. e-Pub 3/2011. PMCID: PMC3069760.
6. Roybal JD, Zang Y, Ahn YH, Yang Y, Gibbons DL, Baird BN, Alvarez C, Thilaganathan N, Liu DD, Saintigny P, Heymach JV, Creighton CJ, Kurie JM. miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res 9(1):25-35, 1/2011. e-Pub 11/2010. PMID: 21115742.
7. Jin N, Cho SN, Raso MG, Wistuba I, Smith Y, Yang Y, Kurie JM, Yen R, Evans CM, Ludwig T, Jeong JW, DeMayo FJ. Mig-6 is required for appropriate lung development and to ensure normal adult lung homeostasis. Development 136(19):3347-56, 10/2009. e-Pub 8/2009. PMCID: PMC2739148.
8. Ahn YH, Kurie JM. MKK4/SEK1 is negatively regulated through a feedback loop involving the E3 ubiquitin ligase itch. J Biol Chem 284(43):29399-404, 10/2009. e-Pub 9/2009. PMCID: PMC2785572.
9. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23(18):2140-51, 9/2009. PMCID: PMC2751985.
10. Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K, Pannicia C, Kurie JM, Threadgill DW. Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 119(9):2702-13, 9/2009. e-Pub 8/2009. PMCID: PMC2735918.
11. Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX, Kurie JM. Distinct biological roles for the notch ligands jagged-1 and jagged-2. J Biol Chem 284(26):17766-74, 6/2009. e-Pub 4/2009. PMCID: PMC2719415.
12. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ. Promotion of Lung Carcinogenesis by COPD-like Airway Inflammation in a K-ras Induced Mouse Model. Am J Respir Cell Mol Biol 40(4):443-53, 4/2009. e-Pub 10/2008. PMCID: PMC2660561.
13. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS One 4(4):e5401, 2009. e-Pub 4/2009. PMCID: PMC2671160.
14. Sun H, Chung WC, Ryu SH, Ju Z, Tran HT, Kim E, Kurie JM, Koo JS. Cyclic AMP-responsive element binding protein- and nuclear factor-kappaB-regulated CXC chemokine gene expression in lung carcinogenesis. Cancer Prev Res (Phila Pa) 1(5):316-28, 10/2008. PMCID: PMC2768131.
15. Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, Pandey A, Kurie JM. Identification of secreted proteins that mediate cell-cell Interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 68(17):7237-7245, 9/2008. PMCID: PMC2562343.
16. Zhang J, Iwanaga K, Choi KC, Wislez M, Raso MG, Wei W, Wistuba II, Kurie JM. Intratumoral epiregulin is a marker of advanced disease in non-Small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila Pa) 1(3):201-207, 10.1158/1940-620/.CAPR-08-0014, 8/2008. e-Pub 3/2008. PMID: 19138957.
17. Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, Johnson FM, Wistuba I, Kurie JM. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952-60, doi: 10.1158/1535-7163.MCT-07-2045, 4/2008. PMID: 18413809.
18. Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, Moghaddam S, Evans CM, Li H, Cai WW, Sato M, Minna JD, Wu H, Creighton CJ, Demayo FJ, Wistuba II, Kurie JM. Pten Inactivation Accelerates Oncogenic K-ras-initiated Tumorigenesis in a Mouse Model of Lung Cancer. Cancer Res 68(4):1119-27, 2/2008. PMCID: PMC2750029.
19. Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, Molldrem JJ, Wistuba II, Powis G, Demayo FJ, Kim CF, Kurie JM. Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One 3(5):e2220, 2008. PMCID: PMC2376060.
20. Zheng S, El-Naggar AK, Kim ES, Kurie JM, Lozano G. A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene 7(48):1-9, 10/2007. e-Pub 5/2007. PMID: 17486075.
21. Sethi G, Ahn KS, Xia D, Kurie JM, Aggarwal BB. Targeted deletion of MKK4 gene potentiates TNF-induced apoptosis through the down-regulation of NF-kappa B activation and NF-kappa B-regulated antiapoptotic gene products. J Immunol 179(3):1926-33, 8/2007. PMID: 17641059.
22. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. C-Jun N-terminal Kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26(18)(18):2658-66, 4/2007. e-Pub 10/2006. PMID: 17057737.
23. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM. Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NFkappaB-dependent pathway. J Biol Chem 282(6):3507-19, 2/2007. e-Pub 12/2006. PMID: 17158870.
24. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, Ma L, Wistuba II, Johnson FM, Kurie JM. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170(1):366-76, 1/2007. PMCID: PMC1762707.
25. Choi K, Creighton CJ, Stivers D, Fujimoto N, Kurie JM. Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One 2(11):1-11, 2007. e-Pub 11/2007. PMCID: PMC2080626.
26. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66(8):4198-207, 4/2006. PMID: 16618742.
27. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65(24):11478-85, 12/2005. PMID: 16357156.
28. Mann KK, Padovani AM, Guo Q, Colosimo AL, Lee HY, Kurie JM, Miller WH. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation. J Clin Invest 115(10):2924-33, 10/2005. e-Pub 9/2005. PMCID: PMC1224295.
29. Cody DD, Nelson CL, Bradley WM, Wislez M, Juroske D, Price RE, Zhou X, Bekele BN, Kurie JM. Murine lung tumor measurement using respiratory-gated micro-computed tomography. Invest Radiol 40(5):263-9, 5/2005. PMID: 15829823.
30. Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 65(8):3226-35, 4/2005. PMID: 15833854.
31. Srinivas H, Juroske DM, Kalyankrishna S, Cody DD, Price RE, Xu XC, Narayanan R, Weigel NL, Kurie JM. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol 25(3):1054-69, 2/2005. PMCID: PMC543999.
32. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65(1):226-35, 2005. PMID: 15665299.
33. Cavanaugh D, Johnson E, Price RE, Kurie JM, Travis EL, Cody DD. In vivo respiratory-gated micro-CT imaging in small-animal oncology models. Mol Imaging 3(1):55-62, 2004. PMID: 15142412.
34. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12(7):660-4, 7/2003. PMID: 12869408.
35. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 6/2003. e-Pub 4/2003. PMID: 12714585.
36. Lee HY, Suh YA, Lee JI, Hassan KA, Mao L, Force T, Gilbert BE, Jacks T, Kurie JM. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin Cancer Res 8(9):2970-5, 9/2002. PMID: 12231543.
37. Li D, Zimmerman TL, Thevananther S, Lee HY, Kurie JM, Karpen SJ. Interleukin-1 beta-mediated suppression of RXR:RAR transactivation of the Ntcp promoter is JNK-dependent. J Biol Chem 277(35):31416-22, 8/2002. e-Pub 6/2002. PMID: 12105223.
38. Suh YA, Lee HY, Virmani A, Wong J, Mann KK, Miller WH, Gazdar A, Kurie JM. Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res 62(14):3945-9, 7/2002. PMID: 12124324.
39. Lee HY, Chun KH, Liu B, Wiehle SA, Cristiano RJ, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer. Cancer Res 62(12):3530-7, 6/2002. PMID: 12068000.
40. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, Roth JA, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 19(38):4432-6, 9/2000. PMID: 10980619.
41. Sueoka N, Lee HY, Walsh GL, Fang B, Ji L, Roth JA, LaPushin R, Hong WK, Cohen P, Kurie JM. Insulin-like growth factor binding protein-6 inhibits the growth of human bronchial epithelial cells and increases in abundance with all-trans-retinoic acid treatment. Am J Respir Cell Mol Biol 23(3):297-303, 9/2000. PMID: 10970819.
42. Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Mol Cell Biol 19(3):1973-80, 3/1999. PMCID: PMC83990.
43. Lee HY, Dohi DF, Kim YH, Walsh GL, Consoli U, Andreeff M, Dawson MI, Hong WK, Kurie JM. All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway. J Clin Invest 101(5):1012-9, 3/1998. PMCID: PMC508652.

Invited Articles

1. Settleman J, Kurie JM. Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer. Cancer Cell 12(1):6-8, 7/2007. PMID: 17613432.
2. Haigis KM, Wistuba II, Kurie JM. Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. Genes Dev 21(4):361-366, 2/2007. PMID: 17322395.

Grant & Contract Support

Title: LH2-driven Collagen Cross-linking as a Novel Mediator of Lung Cancer Metastasis
Funding Source: Lung Cancer Research Foundation
Role: Principal Investigator
Duration: 11/1/2013 - 10/31/2014

Last updated: 7/29/2014